Nucynta Uses

Buy Nucynta here

What is Nucynta?

Nucynta (Nucynta) is an opioid pain medication. An opioid is sometimes called a narcotic.

Nucynta is used to treat moderate to severe pain.

The extended-release form of Nucynta is for around-the-clock treatment of pain that is not controlled by other medicines. It is not for use on an as-needed basis for pain.

Nucynta may also be used for purposes not listed in this medication guide.

Nucynta indications

An indication is a term used for the list of condition or symptom or
illness for which the medicine is prescribed or used by the patient. For
example, acetaminophen or paracetamol is used for fever by the patient,
or the doctor prescribes it for a headache or body pains. Now fever,
headache and body pains are the indications of paracetamol. A patient
should be aware of the indications of medications used for common
conditions because they can be taken over the counter in the pharmacy
meaning without prescription by the Physician.

NUCYNTA® ER (Nucynta) is indicated for the management of:

pain
severe enough to require daily, around-the-clock, long-term opioid
treatment and for which alternative treatment options are inadequate
neuropathic
pain associated with diabetic peripheral neuropathy (DPN) in adults
severe enough to require daily, around-the-clock, long-term opioid
treatment and for which alternative treatment options are inadequate.

Limitations of Usage

Because
of the risks of addiction, abuse, and misuse with opioids, even at
recommended doses, and because of the greater risks of overdose and
death with extended-release opioid formulations, reserve NUCYNTA®
ER for use in patients for whom alternative treatment options (e.g.,
non-opioid analgesics or immediate-release opioids) are ineffective, not
tolerated, or would be otherwise inadequate to provide sufficient
management of pain.
NUCYNTA® ER is not indicated as an as-needed (prn) analgesic.

How should I use Nucynta?

Use Nucynta extended-release tablets as directed by your doctor. Check the label on the medicine for exact dosing instructions.

Nucynta extended-release tablets come with an extra patient information sheet
called a Medication Guide. Read it carefully. Read it again each time
you get Nucynta extended-release tablets refilled.
Take Nucynta extended-release tablets by mouth with or without food. If
stomach upset occurs, take with food to reduce stomach irritation.
Nucynta extended-release tablets must only be taken by mouth. Do not inject or snort Nucynta extended-release tablets.
Do not swallow more than 1 tablet at a time. If your dose requires more than 1 tablet, take only 1 tablet at a time.
Swallow Nucynta extended-release tablets whole. Do not break, cut, crush, chew,
or dissolve the tablet before swallowing it. Contact your doctor if you
cannot swallow Nucynta extended-release tablets whole.
Do not presoak, lick or wet the tablet before you place it in your mouth.
Take each tablet with enough water to be sure that it can be completely
swallowed immediately after you place it in your mouth.
Do not suddenly stop taking Nucynta extended-release tablets. You may have
an increased risk of withdrawal symptoms (eg, nausea, vomiting,
diarrhea, anxiety, shivering). If you need to stop Nucynta extended-release tablets, your doctor will gradually lower your dose.
Nucynta extended-release tablets work best if it is taken at the same time(s) each day. Do not miss any doses.
If you miss a dose of Nucynta extended-release tablets, take it as soon as
possible. If it is almost time for your next dose, skip the missed dose
and go back to your regular dosing schedule. Do not take 2 doses at
once. Do not take more than your prescribed dose in 24 hours.

Ask your health care provider any questions you may have about how to use Nucynta extended-release tablets.

Uses of Nucynta in details

There are specific as well as general uses of a drug or medicine. A medicine
can be used to prevent a disease, treat a disease over a period or cure a
disease. It can also be used to treat the particular symptom of the
disease. The drug use depends on the form the patient takes it. It may
be more useful in injection form or sometimes in tablet form. The drug
can be used for a single troubling symptom or a life-threatening
condition. While some medications can be stopped after few days, some
drugs need to be continued for a prolonged period to get the benefit from
it.

Buy Nucynta

Use: Labeled Indications

Neuropathic pain associated with diabetic peripheral neuropathy:
Extended-release: Management of neuropathic pain associated with
diabetic peripheral neuropathy (DPN) severe enough to require daily,
around-the-clock, long-term opioid treatment and for which alternative
treatment options are inadequate.

Note:
Nucynta ER is generally not recommended as first or second-line therapy
due to a high risk for addiction and safety concerns compared to modest
pain reduction (Pop-Busui 2017).

Pain management:

Immediate
release: Management of acute pain severe enough to require an opioid
analgesic and for which alternative treatments are inadequate in adults.

Extended
release: Management of pain severe enough to require daily,
around-the-clock, long-term opioid treatment and for which alternative
treatments are inadequate.

Limitations
of use: Reserve Nucynta for use in patients for whom alternative
treatment options (eg, nonopioid analgesics, opioid combination
products) are ineffective, not tolerated, or would be otherwise
inadequate to provide sufficient management of pain. Nucynta ER is not
indicated as an as-needed analgesic.

Nucynta description

Opioid analgesic for the treatment of moderate to severe pain. FDA approved on Nov 20, 2008.

Nucynta dosage

NUCYNTA® oral solution is available in one concentration: 20 mg/mL.

Take care when prescribing and administering NUCYNTA®
oral solution to avoid dosing errors, which could result in accidental
overdose and death. Take care to ensure the proper dose is communicated
and dispensed. Include the dose in milliliters (mL) and milligrams (mg)
when writing prescriptions. Always use the enclosed calibrated oral
syringe when administering NUCYNTA® oral solution to ensure the dose is measured and administered accurately.Individualization Of Dosage

As with any opioid drug product, adjust the dosing
regimen for each patient individually, taking into account the
patient’s prior analgesic treatment experience. In the selection of the
initial dose of Nucynta, give attention to the following:

the total daily dose, potency and specific characteristics of the opioid the patient has been taking previously;
the reliability of the relative potency estimate used to calculate the equivalent morphine sulfate dose needed;
the patient’s degree of opioid tolerance;
the general condition and medical status of the patient;
concurrent medications;
the type and severity of the patient’s pain;
risk factors for abuse, addiction or diversion, including a prior history of abuse, addiction or diversion.

The following dosing recommendations, therefore, can only be considered
suggested approaches to what is actually a series of clinical decisions
over time in the management of the pain of each individual patient.
Continual re-evaluation of the patient receiving Nucynta is important,
with special attention to the maintenance of pain control and the
relative incidence of side effects associated with therapy. During
chronic therapy, especially for non-cancer-related pain, periodically
re-assess the continued need for the use of opioid analgesics.

During periods of changing analgesic requirements, including initial
titration, frequent contact is recommended between physician, other
members of the healthcare team, the patient, and the caregiver/family.
Monitor the patient for signs of the respiratory or central nervous system
depression.Initiation Of Therapy

The dose is 2.5 mL (equivalent to 50 mg), 3.75 mL (equivalent to 75 mg), or
5 mL (equivalent to 100 mg) every 4 to 6 hours depending upon pain
intensity.

On the first day of dosing, the second dose may be administered as soon as one hour
after the first dose, if adequate pain relief is not attained with the
first dose. Subsequent dosing is 2.5 mL (equivalent to 50 mg), 3.75 mL
(equivalent to 75 mg), or 5 mL
(equivalent to 100 mg) every 4 to 6 hours and should be adjusted to
maintain adequate analgesia with acceptable tolerability.

Daily doses greater than 700 mg on the first day of therapy and 600 mg on
subsequent days have not been studied and are not recommended.

NUCYNTA® may be given with or without food.Renal Impairment

Use of NUCYNTA® in patients with severe renal impairment is not recommended.

No dosage adjustment is recommended in patients with mild or moderate renal impairment.Hepatic Impairment

The safety and efficacy of NUCYNTA® has not been studied in patients with severe hepatic impairment
(Child-Pugh Score 10-15) and use in this population is not recommended.

Initiate treatment of patients with moderate hepatic impairment (Child-Pugh
Score 7 to 9) with 50 mg no more frequently than once every 8 hours
(maximum of three doses in 24 hours). Further treatment should reflect
maintenance of analgesia with acceptable tolerability, to be achieved by
either shortening or lengthening the dosing interval.

No dosage adjustment is recommended in patients with mild hepatic impairment (Child-Pugh Score 5 to 6).Elderly Patients

In general, recommended dosing for elderly patients with normal renal and
hepatic function is the same as for younger adult patients with normal
renal and hepatic function. Because elderly patients are more likely to
have decreased renal and hepatic function, consideration should be given
to starting elderly patients with a lower range of recommended doses.Cessation Of Therapy

When the patient no longer requires therapy with Nucynta, gradually taper
the dose to prevent signs and symptoms of withdrawal in the physically
dependent patient.Instructions For Use

Concentration and Dispensing: The oral solution contains 20 mg Nucynta per milliliter (mL) and prescriptions should be written in milliliters (mL) and milligrams (mg). An oral syringe is supplied with dose marks corresponding directly to 2.5 mL (equals 50 mg) oral solution, 3.75 mL (equals 75 mg) oral solution, and 5 mL (equals 100 mg) oral solution.

Inform patients of the availability of FDA-approved patient labeling, Instructions for Use, for step-by-step instructions for patients on how to use the medicine bottle and the oral syringe.

How supplied

Dosage Forms And Strengths

NUCYNTA® oral solution: 20 mg/mL oral solution in 100 mL and 200 mL fill bottles with child-resistant closure.

NUCYNTA® oral solution, 20 mg/mL, is available as a clear, colorless solution. Supplied with calibrated syringe:

Bottles of 100 mL (NDC 50458-817-01)

Bottles of 200 mL (NDC 50458-817-02)Storage And Handling

Store up to 25°C (77°F); excursions permitted to 15° to 30°C (59° to 86°F). Store the oral solution bottle upright after opening.

Keep NUCYNTA® in a secure place out of reach of children.

NUCYNTA® oral solution that is no longer needed should be destroyed by flushing down the toilet.

Nucynta interactions

NUCYNTA®
is mainly metabolized by glucuronidation. The following substances have
been included in a set of interaction studies without any clinically
significant finding: acetaminophen, acetylsalicylic acid, naproxen and
probenecid.

The pharmacokinetics
of Nucynta were not affected when gastric pH or gastrointestinal
motility were increased by omeprazole and metoclopramide, respectively.Alcohol, Other Opioids, And Drugs of Abuse

Due to its mu-opioid agonist activity, NUCYNTA®
may be expected to have additive effects when used in conjunction with
alcohol, other opioids, or illicit drugs that cause central nervous
system depression, respiratory depression, hypotension, and profound
sedation, coma or death. Instruct patients not to consume alcoholic
beverages or use prescription or non-prescription products containing
alcohol, other opioids, or drugs of abuse while on NUCYNTA® therapy.Monoamine Oxidase Inhibitors

NUCYNTA®
is contraindicated in patients who are receiving monoamine oxidase
(MAO) inhibitors or who have taken them within the last 14 days due to
potential additive effects on norepinephrine levels which may result in
adverse cardiovascular events.CNS Depressants

Concurrent use of NUCYNTA®
and other central nervous system (CNS) depressants including sedatives
or hypnotics, general anesthetics, phenothiazines, tranquilizers, and
alcohol can increase the risk of respiratory depression, hypotension,
profound sedation or coma. Monitor patients receiving CNS depressants
and NUCYNTA® for signs of respiratory depression and hypotension. When such combined therapy is contemplated, start NUCYNTA® at 1/3 to ½ of the usual dosage and consider using a lower dose of the concomitant CNS depressant.Serotonergic Drugs

There
have been post-marketing reports of serotonin syndrome with the
concomitant use of Nucynta and serotonergic drugs (e.g., SSRIs and
SNRIs). Caution is advised when NUCYNTA®
is co-administered with other drugs that may affect serotonergic
neurotransmitter systems such as SSRIs, SNRIs, MAOIs, and triptans. If
concomitant treatment of NUCYNTA® with a drug affecting the serotonergic neurotransmitter system is clinically warranted, careful observation of the patient is advised.Mixed Agonist/Antagonist Opioid Analgesics

The concomitant use of NUCYNTA®
with mixed agonist/antagonists (e.g., butorphanol, nalbuphine, and
pentazocine) and partial agonists (e.g., buprenorphine) may precipitate
withdrawal symptoms. Avoid the use of agonist/antagonists and partial
agonists with NUCYNTA®.Anticholinergics

The use of NUCYNTA®
with anticholinergic products may increase the risk of urinary
retention and/or severe constipation, which may lead to paralytic ileus.Drug Abuse And Dependence Controlled Substance

NUCYNTA®
contains Tapentadol, a Schedule II controlled substance with a high
potential for abuse similar to fentanyl, methadone, morphine, oxycodone,
and oxymorphone. NUCYNTA® is subject to misuse, abuse, addiction, and criminal diversion.Abuse

All
patients treated with opioids require careful monitoring for signs of
abuse and addiction, because use of opioid analgesic products carries
the risk of addiction even under appropriate medical use.

Drug
abuse is the intentional non-therapeutic use of an over-the-counter or
prescription drug, even once, for its rewarding psychological or
physiological effects. Drug abuse includes, but is not limited to the
following examples: the use of a prescription or over-the-counter drug
to get “high”, or the use of steroids for performance enhancement and muscle build up.

Drug
addiction is a cluster of behavioral, cognitive, and physiological
phenomena that develop after repeated substance use and include: a
strong desire to take the drug, difficulties in controlling its use,
persisting in its use despite harmful consequences, a higher priority
given to drug use than to other activities and obligations, increased
tolerance, and sometimes a physical withdrawal.

“Drug seeking” behavior is very common in addicts, and drug abusers. Drug-seeking tactics include emergency
calls or visits near the end of office hours, refusal to undergo
appropriate examination, testing or referral, repeated claims of loss of
prescriptions, tampering with prescriptions and reluctance to provide
prior medical records or contact information for other treating
physician(s). “Healthcare professional shopping”
(visiting multiple prescribers) to obtain additional prescriptions is
common among drug abusers, people suffering from untreated addiction and
criminals seeking drugs to sell.

Abuse
and addiction are separate and distinct from physical dependence and
tolerance. Physicians should be aware that addiction may not be
accompanied by concurrent tolerance and symptoms of physical dependence
in all addicts. In addition, abuse of opioids can occur in the absence
of true addiction and is characterized by misuse for non-medical
purposes, often in combination with other psychoactive substances.

NUCYNTA®
can be diverted for non-medical use into illicit channels of
distribution. Careful record-keeping of prescribing information,
including quantity, frequency, and renewal requests, as required by law,
is strongly advised.

Proper
assessment of the patient, proper prescribing practices, periodic
re-evaluation of therapy, and proper dispensing and storage are
appropriate measures that help to limit abuse of opioid drugs.Dependence

Both
tolerance and physical dependence can develop during chronic opioid
therapy. Tolerance is the need for increasing doses of opioids to
maintain a defined effect such as analgesia (in the absence of disease
progression or other external factors). Tolerance may occur to both the
desired and undesired effects of drugs, and may develop at different
rates for different effects.

Physical
dependence results in withdrawal symptoms after abrupt discontinuation
or a significant dose reduction of a drug. Withdrawal also may be
precipitated through the administration of drugs with opioid antagonist
activity, e.g., naloxone, nalmefene, or mixed agonist/antagonist
analgesics (pentazocine, butorphanol, buprenorphine, nalbuphine).
Physical dependence may not occur to a clinically significant degree
until after several days to weeks of continued opioid usage. Some or all
of the following can characterize this syndrome: restlessness,
lacrimation, rhinorrhea, yawning, perspiration, chills, piloerection,
myalgia, mydriasis, irritability, anxiety, backache, joint pain,
weakness, abdominal cramps, insomnia, nausea, anorexia, vomiting,
diarrhea, increased blood pressure, respiratory rate, or heart rate.
Withdrawal symptoms may be reduced by tapering NUCYNTA®.

Infants
born to mothers physically dependent on opioids will also be physically
dependent and may exhibit respiratory difficulties and withdrawal
symptoms.

Nucynta side effects

The following adverse reactions are discussed in more detail in other sections of the labeling:

Respiratory Depression
Interaction with Alcohol
Chronic Pulmonary Disease
Hypotensive Effects
Interactions with Other CNS Depressants
Drug abuse, addiction, and dependence
Gastrointestinal Effects
Seizures
Serotonin Syndrome

Clinical Studies Experience

Because
clinical trials are conducted under widely varying conditions, adverse
reaction rates observed in the clinical trials of a drug cannot be
directly compared to rates in the clinical trials of another drug and
may not reflect the rates observed in clinical practice. Based on data
from nine Phase 2/3 studies that administered multiple doses (seven
placebo- and/or active-controlled, one noncontrolled and one Phase 3
active-controlled safety study) the most common adverse reactions
(reported by ≥ 10% in any NUCYNTA® dose group) were: nausea, dizziness, vomiting and somnolence.

The most common reasons for discontinuation due to adverse reactions in the studies described above (reported by ≥ 1% in any NUCYNTA®
dose group) were dizziness (2.6% vs. 0.5%), nausea (2.3% vs. 0.6%),
vomiting (1.4% vs. 0.2%), somnolence (1.3% vs. 0.2%) and headache (0.9%
vs. 0.2%) for NUCYNTA®- and placebo-treated patients, respectively.

Seventy-six percent of NUCYNTA®-treated patients from the nine studies experienced adverse events.

NUCYNTA®
was studied in multiple-dose, active- or placebo-controlled studies, or
noncontrolled studies (n = 2178), in single-dose studies (n = 870), in
open-label study extension (n = 483) and in Phase 1 studies (n = 597).
Of these, 2034 patients were treated with doses of 50 mg to 100 mg of
NUCYNTA® dosed every 4 to 6 hours.

The data described below reflect exposure to NUCYNTA® in 3161 patients, including 449 exposed for 45 days. NUCYNTA® was studied primarily in placebo- and active-controlled studies (n = 2266, and n = 2944, respectively). The population was 18 to 85 years old (mean age 46 years), 68% were female, 75% white and 67% were postoperative. Most patients received NUCYNTA® doses of 50 mg, 75 mg, or 100 mg every 4 to 6 hours.

Table 1 Adverse Reactions Reported by ≥ 1% of NUCYNTA®-Treated
Patients In Seven Phase 2/3 Placebo- and/or Oxycodone-Controlled, One
Non-controlled, and One Phase 3 Oxycodone-Controlled Safety,
Multiple-Dose Clinical Studies System/Organ Class MedDRA Preferred Term NUCYNTA® 21 mg – 120 mg

(n = 2178) % Placebo

(n = 619) %Gastrointestinal disorders Nausea 30 13 Vomiting 18 4 Constipation 8 3 Dry mouth 4 < 1 Dyspepsia 2 < 1 General disorders and administration site conditions Fatigue 3 < 1 Feeling hot 1 < 1 Infections and infestations Nasopharyngitis 1 < 1 Upper respiratory tract infection 1 < 1 Urinary tract infection 1 < 1 Metabolism and nutrition disorders Decreased appetite 2 0 Nervous system disorders Dizziness 24 8 Somnolence 15 3 Tremor 1 < 1 Lethargy 1 < 1 Psychiatric disorders Insomnia 2 < 1 Confusional state 1 0 Abnormal dreams 1 < 1 Anxiety 1 < 1 Skin and subcutaneous tissue disorders Pruritus 5 1 Hyperhidrosis 3 < 1 Pruritus generalized 3 < 1 Rash 1 < 1 Vascular disorders Hot flush 1 < 1

The following adverse drug reactions occurred in less than 1% of NUCYNTA®-treated patients in the pooled safety data from nine Phase 2/3 clinical studies:

Cardiac disorders: heart rate increased, heart rate decreased

Eye disorders: visual disturbance

Gastrointestinal disorders: abdominal discomfort, impaired gastric emptying

General disorders and administration site conditions: irritability, edema, drug withdrawal syndrome, feeling drunk

Immune system disorders: hypersensitivity

Investigations: gamma-glutamyltransferase increased, alanine aminotransferase increased, aspartate aminotransferase increased

Musculoskeletal and connective tissue disorders: involuntary muscle contractions, sensation of heaviness

Nervous system disorders:
hypoesthesia, paresthesia, disturbance in attention, sedation,
dysarthria, depressed level of consciousness, memory impairment, ataxia,
presyncope, syncope, coordination abnormal, seizure

Psychiatric disorders: euphoric mood, disorientation, restlessness, agitation, nervousness, thinking abnormal

Renal and urinary disorders: urinary hesitation, pollakiuria

Respiratory, thoracic and mediastinal disorders: oxygen saturation decreased, cough, dyspnea, respiratory depression

Skin and subcutaneous tissue disorders: urticaria Vascular disorders: blood pressure decreased

In the pooled safety data, the overall incidence of adverse reactions increased with an increased dose of NUCYNTA®, as did the percentage of patients with adverse reactions of nausea, dizziness, vomiting, somnolence, and pruritus. Post-marketing Experience

The following additional adverse reactions have been identified during post-approval use of NUCYNTA®. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to estimate their frequency reliably.

Gastrointestinal disorders: diarrhea

Nervous system disorders: headache

Psychiatric disorders: hallucination, suicidal ideation, panic attack

Cardiac disorders: palpitations

Anaphylaxis, angioedema, and anaphylactic shock have been reported very rarely with ingredients contained in NUCYNTA®. Advise patients how to recognize such reactions and when to seek medical attention.

Nucynta contraindications

You
should not use this medication if you are allergic to Nucynta, or if
you have severe liver or kidney disease, if you are having an asthma
attack, or if you have a bowel obstruction called paralytic ileus.

Do
not use Nucynta if you have used an MAO inhibitor such as furazolidone
(Furoxone), isocarboxazid (Marplan), phenelzine (Nardil), rasagiline
(Azilect), selegiline (Eldepryl, Emsam, Zelapar), or tranylcypromine
(Parnate) in the last 14 days. A dangerous drug interaction could occur,
leading to serious side effects.

Nucynta may be habit-forming and should be used only by the person it was prescribed for. Keep the medication in a secure place where others cannot get to it.

Do
not drink alcohol while you are taking Nucynta. Dangerous side effects
or death can occur when alcohol is combined with a narcotic pain
medicine. Check your food and medicine labels to be sure these products
do not contain alcohol.

Never take Nucynta in larger amounts, or for longer than recommended by your doctor. Tell your doctor if the medicine seems to stop working as well in relieving your pain.

This
medication may impair your thinking or reactions. Avoid driving or
operating machinery until you know how Nucynta will affect you.

Do
not stop using Nucynta suddenly, or you could have unpleasant
withdrawal symptoms. Ask your doctor how to avoid withdrawal symptoms
when you stop using Nucynta.

Active ingredient matches for Nucynta:

Tapentadol

Tapentadol HCl in Singapore.

Tapentadol hydrochloride

Unit description / dosage (Manufacturer)Price, USD
Nucynta tablet, film coated 100 mg/1 (Stat Rx USA (US))
Nucynta tablet 50 mg/1 (Lake Erie Medical DBA Quality Care Products LLC (US))
Nucynta solution 20 mg/mL (Janssen Pharmaceuticals, Inc. (US))
Nucynta tablet, film coated 50 mg/1 (Stat Rx USA (US))
Nucynta tablet, film coated 75 mg/1 (Lake Erie Medical DBA Quality Care Products LLC (US))

List of Nucynta substitutes (brand and generic names):

LUCYNTA
LUCYNTA 100MG TABLET 1 strip / 10 tablets each (Lupin Ltd)$ 2.89
Nucynta CR (Canada)
Nucynta CR tablet / extended-release 50 mg (Janssen Inc (Canada))
Nucynta CR tablet / extended-release 250 mg (Janssen Inc (Canada))
Nucynta CR tablet / extended-release 100 mg (Janssen Inc (Canada))
Nucynta CR tablet / extended-release 150 mg (Janssen Inc (Canada))
Nucynta CR tablet / extended-release 200 mg (Janssen Inc (Canada))
Nucynta ER
Nucynta ER tablet, film coated, extended release 50 mg/1 (Lake Erie Medical DBA Quality Care Products LLC (US))
Nucynta ER tablet, film coated, extended release 200 mg/1 (Janssen Pharmaceuticals, Inc. (US))
Nucynta ER tablet, film coated, extended release 250 mg/1 (Janssen Pharmaceuticals, Inc. (US))
Nucynta ER tablet, film coated, extended release 100 mg/1 (Janssen Pharmaceuticals, Inc. (US))
Nucynta ER tablet, film coated, extended release 150 mg/1 (Janssen Pharmaceuticals, Inc. (US))

Nucynta ER Extended-Release Tablets Nucynta Extended-Release (Canada)
Nucynta Extended-release tablet / extended-release 100 mg (Janssen Inc (Canada))
Nucynta Extended-release tablet / extended-release 150 mg (Janssen Inc (Canada))
Nucynta Extended-release tablet / extended-release 200 mg (Janssen Inc (Canada))
Nucynta Extended-release tablet / extended-release 50 mg (Janssen Inc (Canada))
Nucynta Extended-release tablet / extended-release 250 mg (Janssen Inc (Canada))
Nucynta IR (Canada)
Nucynta Ir tablet / immediate release 50 mg (Janssen Inc (Canada))
Nucynta Ir tablet / immediate release 75 mg (Janssen Inc (Canada))
Nucynta Ir tablet / immediate release 100 mg (Janssen Inc (Canada))
Nucynta Solution NUROLIKA (India)
NUROLIKA tab 50 mg x 10’s (Aronex)
NUTAPOLI (India)
NUTAPOLI tab 50 mg x 10’s (Zenon)
Paintadol (India)
Paintadol 50mg TAB / 10 (Andic)
PAINTADOL tab 50 mg x 10’s (Andic)
Palexia (Estonia, Spain, Sweden, Switzerland, United Kingdom)
Palexia 100mg (Switzerland)
Palexia 20mg/ml (Switzerland)
Palexia 50mg (Austria, Israel, Luxembourg, Switzerland)
Palexia 75mg (Israel, Luxembourg, Switzerland)
Palexia Depot (Norway, Sweden)
Palexia IR (Australia)
Palexia PR (Cyprus)
Palexia retard (Estonia, Germany)
Palexia Retard 100mg (Austria, Luxembourg, Switzerland)
Palexia Retard 150mg (Austria, Luxembourg, Switzerland)
Palexia Retard 200mg (Austria, Luxembourg, Switzerland)
Palexia Retard 250mg (Austria, Luxembourg, Switzerland)
Palexia Retard 25mg (Switzerland)
Palexia Retard 50mg (Austria, Luxembourg, Switzerland)
Palexia SR (United Kingdom)
Palexia SR 100mg (Israel)
See 184 substitutes for Nucynta

References

PubChem. “Tapentadol”. https://pubchem.ncbi.nlm.nih.gov/com…
DrugBank. “Tapentadol”. http://www.drugbank.ca/drugs/DB06204
MeSH. “MeSH Tree: MeSH (Medical Subject Headings) is the NLM controlled vocabulary thesaurus used for indexing articles for PubMed.”. http://www.nlm.nih.gov/mesh/meshhome…

ia, Finland, France, Germany, Guatemala, Honduras, Hong Kong, Hungary, Iceland, India, Indonesia, Israel, Italy, Latvia, Lithuania, Luxembourg, Malaysia, Malta, Mexico, Netherlands, New Zealand, Norway, Oman, Panama, Philippines, Poland, Portugal, Romania, Russian Federation, Singapore, Slovenia, Spain, Sri Lanka, Sweden, Switzerland, Taiwan, Thailand, Tunisia, Vietnam) Cream; Topical; Calcipotriol Hydrate 0.005% (Croslands (Ranbaxy Laboratories Ltd) Ointment; Topical; Calcipotriol Hydrate 0.005% (Croslands (Ranbaxy Laboratories Ltd) Solution; Topical; Calcipotriol Hydrate 0.005% (Croslands (Ranbaxy Laboratories Ltd) DAIVONEX Cream/ Gel/ Ointment / 50mcg per gm / 30gm units (Croslands (Ranbaxy Laboratories Ltd)$ 11.03 Daivonex 50 mcg/1 g x 30 g (Croslands (Ranbaxy Laboratories Ltd)$ 30.18 Daivonex 50 mcg/1 mL x 30 mL (Croslands (Ranbaxy Laboratories Ltd)$ 30.44 0.005 % w/w x 15g (Croslands (Ranbaxy Laboratories Ltd)$ 10.37 0.005 % w/w x 30g (Croslands (Ranbaxy Laboratories Ltd)$ 16.95 0.005 % w/v x 30ml (Croslands (Ranbaxy Laboratories Ltd)$ 16.95 Daivonex 0.005% w/v S-SOLN / 30ml (Croslands (Ranbaxy Laboratories Ltd)$ 16.95 Daivonex 0.005% w/v OINT / 15g (Croslands (Ranbaxy Laboratories Ltd)$ 10.37 Daivonex 0.005% w/v OINT / 30g (Croslands (Ranbaxy Laboratories Ltd)$ 16.95 Daivonex 50 mcg/1 g x 30 g x 1’s (Croslands (Ranbaxy Laboratories Ltd) Daivonex 50 mcg/1 mL x 30 mL x 1’s (Croslands (Ranbaxy Laboratories Ltd)$ 22.84 Daivonex 0.005 % x 30 g x 1’s (Croslands (Ranbaxy Laboratories Ltd)$ 23.93 Daivonex 50 mcg/1 g x 1 tube 30 g (Croslands (Ranbaxy Laboratories Ltd) Daivonex 50 mcg/1 mL x 1 Bottle 30 mL (Croslands (Ranbaxy Laboratories Ltd) Daivonex Skin 30 gm Ointment (Croslands (Ranbaxy Laboratories Ltd)$ 0.37 Daivonex Skin 30 gm Cream Cream (Croslands (Ranbaxy Laboratories Ltd)$ 15.84 Daivonex Skin 30 ml Solution (Croslands (Ranbaxy Laboratories Ltd)$ 15.84 Daivonex Skin 15 gm Ointment (Croslands (Ranbaxy Laboratories Ltd)$ 10.37 Daivonex oint 50 mcg/g 30 g x 1’s (Croslands (Ranbaxy Laboratories Ltd)$ 30.18 Daivonex scalp soln 50 mcg/mL 30 mL x 1’s (Croslands (Ranbaxy Laboratories Ltd)$ 30.44 Daivonex cream 50 mcg/g 30 g x 1’s (Croslands (Ranbaxy Laboratories Ltd)$ 29.58 DAIVONEX oint 0.005 % w/w x 15g (Croslands (Ranbaxy Laboratories Ltd)$ 10.37 DAIVONEX oint 0.005 % w/w x 30g (Croslands (Ranbaxy Laboratories Ltd)$ 16.95 DAIVONEX scalp soln 0.005 % w/v x 30ml (Croslands (Ranbaxy Laboratories Ltd)$ 16.95 Daivonex 0.005% (Egypt) Daivonex 50μg/g (Germany) Daivonex 50μg/ml (Germany) Daivonex D.A.C. (Iceland) Daivonex Scalp Solution Solution; Topical; Calcipotriol Hydrate 0.005% Darederm (India) Darederm Betamethasone valerate 0.61mg, Gentamycin sulphate 1 mg, Tolnaftate 10 mg, Iodochlorhydroxyquinoline 10mg/1 g. TUBE / 5g (Mount Mettur Pharmaceuticals Ltd)$ 0.17 5g (Mount Mettur Pharmaceuticals Ltd)$ 0.17 Darederm Skin 5 gm Cream (Mount Mettur Pharmaceuticals Ltd)$ 0.17 DAREDERM cream 5g (Mount Mettur Pharmaceuticals Ltd)$ 0.17 See 2688 substitutes for Daivobet

References

DailyMed. “CALCIPOTRIENE HYDRATE: DailyMed provides trustworthy information about marketed drugs in the United States. DailyMed is the official provider of FDA label information (package inserts).”. https://dailymed.nlm.nih.gov/dailyme…
DailyMed. “BETAMETHASONE: DailyMed provides trustworthy information about marketed drugs in the United States. DailyMed is the official provider of FDA label information (package inserts).”. https://dailymed.nlm.nih.gov/dailyme…
PubChem. “betamethasone”. https://pubchem.ncbi.nlm.nih.gov/com…